Robeco Institutional Asset Management B.V. Has $14 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Robeco Institutional Asset Management B.V. raised its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 8.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 548,761 shares of the biopharmaceutical company's stock after buying an additional 43,926 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.09% of Royalty Pharma worth $13,999,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. boosted its stake in Royalty Pharma by 58.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company's stock worth $84,915,000 after buying an additional 1,103,341 shares in the last quarter. Two Sigma Advisers LP grew its stake in Royalty Pharma by 44.7% during the third quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company's stock worth $85,809,000 after buying an additional 936,900 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Royalty Pharma during the 3rd quarter valued at $14,898,000. Geode Capital Management LLC increased its stake in shares of Royalty Pharma by 6.1% in the third quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company's stock valued at $205,562,000 after buying an additional 417,490 shares in the last quarter. Finally, Bank of Montreal Can increased its position in Royalty Pharma by 186.0% in the 3rd quarter. Bank of Montreal Can now owns 445,937 shares of the biopharmaceutical company's stock valued at $12,580,000 after acquiring an additional 290,019 shares in the last quarter. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Stock Down 0.2 %

NASDAQ:RPRX traded down $0.07 on Tuesday, hitting $31.26. 3,605,955 shares of the company's stock were exchanged, compared to its average volume of 4,225,030. The firm has a 50-day moving average price of $27.43 and a 200-day moving average price of $27.55. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $32.21. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. The company has a market cap of $18.42 billion, a P/E ratio of 16.20 and a beta of 0.49.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be paid a $0.22 dividend. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.82%. Royalty Pharma's dividend payout ratio (DPR) is currently 43.52%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on RPRX shares. TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a research report on Tuesday, December 24th. Citigroup lowered their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a "buy" rating for the company in a research report on Friday, October 25th. Finally, StockNews.com upgraded shares of Royalty Pharma from a "hold" rating to a "buy" rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $41.67.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.